ConductScience.org, home

Comparison · NCT01380197-2bf36da4

Randomizing Particiipants to Morphine vs Randomization to Nubain: Number of Participants Who Experienced Pain Relief

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Randomizing Particiipants to Morphine vs Randomization to Nubain: Number of Participants Who Experienced Pain Relief. Trial comparisons, record NCT01380197-2bf36da4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01380197-2bf36da4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.10.02790.301wilson
Risk in group 20.10.02790.301wilson
Risk difference, group 1 minus group 20-0.2140.214newcombe hybrid score
Risk ratio, group 1 over group 210.1566.42log
Odds ratio, group 1 over group 210.1277.89log
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Randomizing Particiipants to Morphine
Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis~Morphine: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).
220OG000
Group 2Randomization to Nubain
Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients~Nubain: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).
220OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Experienced Pain Relief
Description
Time frame
2 days
Population

Source ClinicalTrials.gov

Trial

Title
Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
NCT number
NCT01380197
Phases
PHASE3
Conditions
Pain, Sickle Cell Disease
Interventions
Morphine, Nubain
Lead sponsor
Children's Healthcare of Atlanta
Results first posted
2015-02-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01380197-2bf36da4